Tumor Immunotherapy Targeting Immune Checkpoint B7-H3
10.13865/j.cnki.cjbmb.2025.05.1036
- VernacularTitle:靶向免疫检查点B7-H3对肿瘤的免疫治疗作用
- Author:
Jia-Yue CHEN
1
;
Feng WANG
1
Author Information
1. 北京理工大学生命学院,北京 100081
- Publication Type:Journal Article
- Keywords:
immune checkpoint B7-H3;
tumor microenvironment(TME);
targeted therapy;
drug devel-opment
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(7):933-946
- CountryChina
- Language:Chinese
-
Abstract:
B7-H3,also known as CD276,is a new immune checkpoint discovered in recent years and belongs to the B7 superfamily.It has low or no expression in normal human tissues,but abnormal expres-sion in immune cells and tumor tissues.B7-H3 is related to tumor immunotherapy and plays a dual role of co-stimulation/co-inhibition in tumor microenvironment(TME).Therefore,targeting B7-H3 can achieve accurate tumor immunotherapy,thus enhancing anti-tumor immune responses.As the immune function of B7-H3 in tumors has been widely revealed,targeted drugs have also been developed and have entered preclinical and clinical trials.However,the different forms and functions of B7-H3 in human body are still controversial,the human origin structure has not been analyzed,and its potential receptor has not been confirmed.In this paper,the structure and function of B7-H3,its physiological role in tumor immu-nity and the research progress of targeted therapy are reviewed.In the future,it is necessary to further explore the exact evidence of B7-H3 in tumor immunotherapy and the challenges and limitations of exist-ing therapies,in order to provide new directions and approaches for drug development targeting B7-H3.
